HALO logo
halo search icon
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
KALV · NAS

KalVista Pharmaceuticals, Inc.

US$26.81

Price Arrow0.04 (0.149%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusHALO AllHammer Bearish (Realtime)Near 52 Week HighNear Resistance
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

KalVista Pharmaceuticals, Inc. Overview

KALV Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About KALV

icon

Telephone

1.857.999.0075

icon

Address

200 Crossing Boulevard, Framingham, MA 01702

Description

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KALV Price Chart

Key Stats

Market Cap

US$1.43B

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 9.83 - 26.85

Trade Value (12mth)

US$7,797,237.00

1 week

0.15%

1 month

37.78%

YTD

73.16%

1 year

125.53%

All time high

129.11

Key Fundamentals

EPS 3 yr Growth

-3.10%

EBITDA Margin

-231.40%

Operating Cashflow

-$82m

Free Cash Flow Return

-34.60%

ROIC

-69.60%

Interest Coverage

-8.80

Quick Ratio

5.50

Other Data

Shares Outstanding (Fully Diluted)

55m

HALO Sector

Healthcare

Next Company Report Date

15-Jul-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

KALV Announcements

Latest Announcements

DateAnnouncements
15 May 26
15 May 26
06 May 26
30 April 26
29 April 26

KALV Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-3.44-3.69-3.23locklocklock
EPS (Fully Diluted)
$locklocklocklock-3.44-3.69-3.23locklocklock
Growth
%locklocklocklock-3.4-7.312.6locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of KalVista Pharmaceuticals, Inc. (KALV:NAS)?
Halo FAQ
The current share price of KalVista Pharmaceuticals, Inc. (KALV:NAS) is USD$26.81.
What is the 52-week high share price for KalVista Pharmaceuticals, Inc. (KALV:NAS)?
Halo FAQ
The 52-week high share price for KalVista Pharmaceuticals, Inc. (KALV:NAS) is USD$26.85.
What is the 52-week low share price for KalVista Pharmaceuticals, Inc. (KALV:NAS)?
Halo FAQ
The 52-week low share price for KalVista Pharmaceuticals, Inc. (KALV:NAS) is USD$9.83.
What is the dividend yield for KalVista Pharmaceuticals, Inc. (KALV:NAS)?
Halo FAQ
KalVista Pharmaceuticals, Inc. (KALV:NAS) does not pay a dividend.
What was KalVista Pharmaceuticals, Inc. (KALV:NAS) last dividend payment?
Halo FAQ
KalVista Pharmaceuticals, Inc. (KALV:NAS) does not pay a dividend.
What is the franking level for KalVista Pharmaceuticals, Inc. (KALV:NAS)?
Halo FAQ
KalVista Pharmaceuticals, Inc. (KALV:NAS) has a franking level of 0.00%.
In which sector is KalVista Pharmaceuticals, Inc. (KALV:NAS) classified?
Halo FAQ
KalVista Pharmaceuticals, Inc. (KALV:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.